Kolexia
Cupissol Didier Oncologie médicale
Cupissol Didier
Oncologie médicale
Icm Montpellier
Montpellier, France
151 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sarcomes Carcinomes Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Métastase tumorale Léiomyosarcome Récidive tumorale locale Mélanome

Collaborateurs

Voir plus
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Bertucci Francois
Bertucci Francois
Centre Paoli-Calmettes, Marseille, France
Chevreau Christine
Chevreau Christine
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Bompas Emmanuelle
Bompas Emmanuelle
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
MSD
3 collaboration(s)
Dernière en 2020
Merck-Serono
2 collaboration(s)
Dernière en 2023
BMS
1 collaboration(s)
Dernière en 2020
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
The Lancet. Healthy longevity   05 mars 2024
French national standard for the treatment of squamous cell carcinoma of upper aero-digestive tract - General principles of treatment.
Bulletin du cancer   27 février 2024
National standard for the treatment of squamous cell carcinoma of upper aerodigestive tract.
Bulletin du cancer   08 février 2024
ELAN-UNFIT: Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Essai Clinique (Merck-Serono)   07 février 2024
REGOBONE: A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Essai Clinique (Unicancer)   06 novembre 2023
Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib.
Bulletin du cancer   23 mars 2023
TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
Essai Clinique (Groupe d'Oncologie Radiothérapie Tête Et Cou)   22 août 2022
Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.
Cancer research   25 avril 2022
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
ESMO Immuno-Oncology Congress 2021 08-11 December 2021   01 décembre 2021
LBA58 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021